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Abstract
Background: Observational studies have shown that milk consumption is inversely associated with colorectal,
bladder, and breast cancer risk, but positively associated with prostate cancer. However, whether the associations
reflect causality remains debatable. We investigated the potential causal associations of milk consumption with the
risk of colorectal, bladder, breast, and prostate cancer using a genetic variant near the LCT gene as proxy for milk
consumption.
Methods: We obtained genetic association estimates for cancer from the UK Biobank (n = 367,643 women and
men), FinnGen consortium (n = 135,638 women and men), Breast Cancer Association Consortium (n = 228,951
women), and Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome
consortium (n = 140,254 men). Milk consumption was proxied by a genetic variant (rs4988235 or rs182549)
upstream of the gene encoding lactase, which catalyzes the breakdown of lactose.
Results: Genetically proxied milk consumption was associated with a reduced risk of colorectal cancer. The odds
ratio (OR) for each additional milk intake increasing allele was 0.95 (95% confidence interval [CI] 0.91–0.99; P =
0.009). There was no overall association of genetically predicted milk consumption with bladder (OR 0.99; 95% CI
0.94–1.05; P = 0.836), breast (OR 1.01; 95% CI 1.00–1.02; P = 0.113), and prostate cancer (OR 1.01; 95% CI 0.99–1.02;
P = 0.389), but a positive association with prostate cancer was observed in the FinnGen consortium (OR 1.07; 95% CI
1.01–1.13; P = 0.026).
Conclusions: Our findings strengthen the evidence for a protective role of milk consumption on colorectal cancer
risk. There was no or limited evidence that milk consumption affects the risk of bladder, breast, and prostate cancer.
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Background
Milk products are major components of the traditional
Western diets and are rich sources of essential nutrients
[1]. The association between self-reported milk con-
sumption and cancer risk has been extensively studied.
Available observational data indicate that milk consump-
tion is associated with a reduced risk of colorectal cancer
[2–7], an association that may be mediated, at least in
part, by calcium [7–10]. The World Cancer Research
Fund and American Institute for Cancer Research have
concluded that there is convincing evidence that con-
sumption of dairy foods and taking calcium supplements
decrease the risk of colorectal cancer [7]. Inconclusive
observational evidence further suggests that milk con-
sumption is inversely associated with risk of bladder [4,
11, 12] and breast cancer [4, 7, 13, 14], positively associ-
ated with prostate cancer [4, 7, 15–17], but not associ-
ated with other cancers [4, 7, 18, 19]. However, as
observational studies are susceptible to methodological
biases, particularly confounding and reverse causality,
the causal role of milk consumption for cancer risk re-
mains unestablished.
Milk sugar (lactose) is digested by the enzyme lactase,
which is encoded by the lactase gene (LCT) and pro-
duced by cells in the small intestine. A single nucleotide
polymorphisms (SNP) upstream of the LCT gene is asso-
ciated with lactase persistence (the continued activity of
the lactase enzyme in adulthood) and with higher milk
consumption in European populations [20, 21]. We
assessed the potential causal associations of milk con-
sumption with the risk of colorectal, bladder, breast, and




Genetic association estimates for colorectal, bladder,
breast, and prostate cancer were estimated in the UK
Biobank cohort, which enrolled about 500,000 adults (37
to 73 years of age) between 2006 and 2010 [22]. In the
present analysis, we included 367,643 unrelated partici-
pants of European ancestry to diminish population
stratification bias and used follow-up data to March 31,
2017. Classification of each cancer site has been reported
previously [23]. Analyses of genotype-cancer associations
were done only in women for breast cancer and only in
men for prostate cancer. We adjusted the association es-
timates for age, sex (in analyses of colorectal and bladder
cancer), and the first ten genetic principal components
through logistic regression.
We additionally obtained summary-level data (i.e., beta
coefficients and standard errors) for genetic associations
with colorectal, bladder, breast, and prostate cancer from
the FinnGen consortium (including up to 135,638
women and men of Finnish ancestry) [24]. The equiva-
lent summary-level data for breast and prostate cancer
were acquired respectively from the Breast Cancer Asso-
ciation Consortium (BCAC) (including 228,951 women
of European ancestry) [25] and the Prostate Cancer As-
sociation Group to Investigate Cancer Associated Alter-
ations in the Genome (PRACTICAL) consortium
(including 140,254 men of European ancestry) [26]. All
genetic association estimates were calculated by logis-
tic regression comparing cases and controls and ad-
justed for genetic principal components (the first ten
in the FinnGen consortium and BCAC, and the first
seven in the PRACTICAL consortium). Some studies
further adjusted for study-relevant covariates, such as
age, sex (in analyses of colorectal and bladder cancer
in the FinnGen consortium), country, and genotyping
batch.
The UK Biobank and studies included in the consortia
had been approved by an ethical review board, and all
participants provided informed consent. The current
analyses were approved by the Swedish Ethical Review
Authority.
Genetic instrument
As a genetic instrument for milk consumption in our
primary analyses, we used rs4988235, which is located
upstream from the LCT gene and is associated with milk
consumption in European populations [20, 21]. In a sub-
cohort of 12,722 participants of the European Prospect-
ive Investigation into Cancer and Nutrition-InterAct
study, the median milk consumption was 162 g/day
(25th to 75th percentile, 37 to 300 g/day) and each add-
itional milk intake increasing allele of rs4988235 was as-
sociated with an increase in milk consumption of 17.1 g/
day (P = 2 × 10−7) [20]. In a population-based cohort
study of 73,715 Danish individuals, milk consumption
increased with 0.58 (95% CI 0.49–0.68) glasses/week
(P = 9 × 10−36) for each additional milk intake increasing
allele of rs4988235 [21]. In the Danish cohort, the SNP
explained 2% of the variance in milk intake, and the F-
statistic was 515 [21]. Rs4988235 was not available in
the FinnGen consortium, and a proxy SNP (rs182549) in
complete linkage disequilibrium was used.
Another SNP (rs3754686) nearby the LCT gene has
been shown to be strongly associated with milk con-
sumption in Mediterranean and American populations
[27]. Rs3754686 was available in all data sources and
was in strong linkage disequilibrium with rs4988235
(R2 = 0.71 in the CEU [Utah residents from North and
West Europe] population, 0.95 in the British population,
and 0.77 in the Finnish population; LDlink version 4.2
[28]). Rs3754686 was used as an instrument for milk
consumption in a complementary analysis.
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Statistical analysis
Odds ratio (OR) estimates were reported per additional
milk intake increasing allele. Estimates from the different
data sources were combined using fixed-effects meta-
analysis. The amount of heterogeneity between estimates
was quantified using the I2 statistic [29]. All analyses
were conducted using Stata/SE 14.2 (Stata Corporation,
College Station, TX, USA).
Results
Genetically predicted milk consumption was inversely
associated with colorectal cancer risk in the combined
analysis of the UK Biobank and FinnGen consortium
(Fig. 1). The OR for each additional milk intake increas-
ing allele was 0.95 (95% confidence interval [CI] 0.91–
0.99; P = 0.009), without evidence of heterogeneity be-
tween estimates from the two studies (I2 = 0%). Genetic-
ally predicted milk consumption was not associated with
bladder cancer (OR 0.99; 95% CI 0.94–1.05; P = 0.836;
I2 = 0%) or breast cancer (OR 1.01; 95% CI 1.00–1.02;
P = 0.113; I2 = 5.4%) (Fig. 1). In the BCAC, results were
null for both estrogen receptor-positive (OR 1.00; 0.98–
1.02; P = 0.999) and estrogen receptor-negative (OR 1.01;
95% CI 0.98–1.04; P = 0.494) breast tumors. No overall
association was observed between genetically predicted
milk consumption and prostate cancer (OR 1.01; 95% CI
0.99–1.02; P = 0.389), but there was moderate heterogen-
eity among estimates from different data sources (I2 =
54%) and a positive association was observed in the
FinnGen consortium (OR 1.07; 95% CI 1.01–1.13;
P = 0.026) (Fig. 1).
Results were similar when using rs3754686 as an in-
strument for milk consumption. The ORs in these ana-
lyses for each additional milk intake increasing allele
were 0.94 (95% CI 0.90–0.90; P = 0.003) for colorectal
cancer, 1.01 (95% CI 0.95–1.07; P = 0.767) for bladder
cancer, 1.00 (95% CI 0.99–1.01; P = 0.974) for breast
cancer, and 1.01 (95% CI 0.99–1.03; P = 0.265) for pros-
tate cancer.
Discussion
This genetic study found that higher milk consumption
was associated with a reduced risk of colorectal cancer,
consistent with findings of observational studies [2–7].
However, our findings do not support observational
findings that higher milk consumption is associated with
Fig. 1 Associations of higher milk consumption with colorectal, bladder, breast, and prostate cancer. Estimates are per milk intake increasing
allele of rs4988235. In the FinnGen consortium, a proxy variant (rs182549) in complete linkage disequilibrium with rs4988235 was used. BCAC
Breast Cancer Association Consortium, CI confidence interval, OR odds ratio, PRACTICAL Prostate Cancer Association Group to Investigate Cancer
Associated Alterations in the Genome consortium
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a lower risk of bladder and breast cancer or with a
higher risk of prostate cancer, though a positive associ-
ation between genetically predicted milk consumption
and prostate cancer was found in the FinnGen consor-
tium. For bladder cancer, observational studies have re-
ported a protective association mainly with the
consumption of fermented milk products (cultured milk,
yogurt, and cheese) [12, 30]. The lactase persistence vari-
ant is not associated with yogurt and cheese consump-
tion [20, 21].
Studies of genetically predicted milk consumption in
relation to site-specific cancers are scarce. No associ-
ation was observed between rs4988235 and colorectal
cancer in small case-control studies conducted in
Turkey (44 cases and 48 controls) [31] and Italy (306
cases and 311 controls) [32]. Lactase persistence was
non-significantly positively associated with prostate can-
cer risk in a meta-analysis of three studies, including a
case-control study nested in the European Prospective
Investigation into Cancer and Nutrition study (630 cases
and 873 controls) and case-control studies of Finnish
(1229 cases and 473 controls) and Swedish (2924 cases
and 1842 controls) men [33]. The combined OR was
1.12 (95% CI 0.96–1.32) [33] and ranged from 1.06 to
1.16 in individual studies [33, 34]. This finding is con-
sistent with the result observed in the FinnGen consor-
tium. The reason for the disparate findings for
rs4988235 and prostate cancer risk might be related to
different amounts of milk consumed in different popula-
tions. Finland is the country with the highest per capita
milk consumption and Sweden also has high consump-
tion [35]. If there is a threshold effect of milk consump-
tion on prostate cancer risk, an association between the
lactase persistence variant and prostate cancer might
only be seen in populations with high milk
consumption.
The observed protective association between milk con-
sumption and colorectal cancer may be mediated, at
least partly, by calcium. Calcium supplementation has
been demonstrated to reduce the risk of colorectal aden-
omas in randomized controlled trials [8] and colorectal
cancer in observational studies [9, 10]. In one of the tri-
als, the protective effect of calcium supplementation on
colorectal adenomas was confined to individuals with a
normal body mass index [36]. Calcium may have a local
protective effect on colorectal cancer by binding second-
ary bile acids and free fatty acids in the lumen of the
bowel, thereby inhibiting their toxic effects on colono-
cytes and suppressing mucosal proliferation [37, 38].
Stimulation of the calcium-sensing receptor in colono-
cytes is another possible mechanism [39]. Calcium sup-
plementation has also been shown to lead to a non-
significant increased expression of tight junction pro-
teins, suggesting that calcium may play a role in
maintaining the integrity of the intestinal mucosal bar-
rier [40].
Other compounds in milk that might protect against
colorectal cancer include butyric acid (a short-chain fatty
acid), conjugated linoleic acid, sphingolipids, and lacto-
ferrin [37, 38, 41]. Almost 70% of the fat in milk is satu-
rated of which about 11% comprises short-chain fatty
acids (half of which is butyric acid) [42]. Milk fat also
contains conjugated linoleic acid [42]. The anti-
carcinogenic effects of this fatty acid have been demon-
strated in animal models [37], but human data are lim-
ited to a Swedish cohort study which revealed a
statistically significant inverse association between con-
jugated linoleic acid intake and risk of colorectal cancer
[43]. Lactoferrin is an iron-binding glycoprotein present
in human and bovine milk. It enhances immune func-
tion and inhibits colorectal carcinogenesis in animal
models [44]. In addition, a randomized controlled trial
found that orally administered lactoferrin for 12 months
retarded the growth of adenomatous colorectal polyps in
the subgroup of participants 63 years of age or younger
[44]. Milk consumption may also influence colorectal
cancer risk by altering the gut microbiota. Higher milk
consumption has been associated with greater micro-
biota richness and more abundant Faecalibacterium and
Fusobacterium but less Bacteroides in humans [45]. A
recent study showed that supplementing the diet of
aging mice with bovine milk increased intestinal levels
of short-chain fatty acids through modulation of gut
microbiota [46].
There is suggestive or weak evidence from observa-
tional studies that milk consumption might increase
prostate cancer risk via calcium [7, 17] and insulin-like
growth factor 1 [47]. A recent Mendelian randomization
study showed that genetically predicted insulin-like
growth factor 1 levels were significantly positively associ-
ated with prostate cancer in the UK Biobank and non-
significantly positively associated with prostate cancer in
the PRACTICAL consortium and BioBank Japan [48].
Milk is also a rich source of phosphorus, which was ob-
served to be positively associated with the risk of pros-
tate cancer in a cohort of US health professionals [49].
Findings from a Mendelian randomization study can
be biased if the genetic instrument affects the outcome
through a pathway other than via the exposure of inter-
est. In this case, it is plausible that a high milk consump-
tion results in lower or higher consumption of other
foods. In fact, the milk intake increasing allele of
rs4988235 has been shown to be modestly associated
with lower consumption of fruits (− 7.0 g/day, P = 0.01),
cereals (− 3.4 g/day, P = 0.03), poultry (− 0.8 g/day, P =
6 × 10−3), and wine (− 4.8 g/day, P = 0.03) but with higher
consumption of potatoes (3.0 g/day, P = 5 × 10−3) in
European individuals [20]. An association between the
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milk intake increasing allele of rs4988235 and lower
consumption of fruits as well as vegetables was also ob-
served in a Danish population [50]. There is some evi-
dence that low consumption of fruits and vegetables
might increase the risk of colorectal cancer [5, 7]. Thus,
any effect of fruit and vegetable consumption would be
expected to attenuate the association between genetically
predicted milk consumption and risk of colorectal can-
cer towards the null and cannot explain our finding.
The milk intake increasing allele of rs4988235 has also
been associated with higher body mass index in several
studies [51–53] but not all [20, 21], as well as positively
associated with height [54]. Considering that greater
body mass index and height are associated with an in-
creased risk of colorectal cancer [55, 56], these factors
also cannot mediate the inverse association between
genetically predicted milk consumption and colorectal
cancer. Rs4988235 is not associated with other potential
colorectal cancer risk factors, such as red meat, proc-
essed meat, and alcohol consumption, type 2 diabetes,
physical activity, and smoking, and is also not associated
with education level in European individuals [20, 21, 50].
Variations in allele frequency of the lactase persistence
variant across populations can lead to population strati-
fication bias. In this MR study, we reduced such bias by
confining the analyses to individuals of European ances-
try. Furthermore, all studies adjusted for population sub-
structure through genetic principal components. Results
for genetically predicted milk consumption and colorec-
tal cancer risk were also consistent in the relatively
homogenous study sample of Finnish participants in-
cluded in the FinnGen consortium, suggesting that
population stratification bias is unlikely to explain this
association. A possible explanation for the observed
positive association between genetically predicted milk
consumption and prostate cancer risk in FinnGen might
be related to that the FinnGen population is more
homogenous than the populations in the other two data
sources.
Conclusions
Our findings strengthen the evidence for a protective
role of milk consumption on colorectal cancer risk.
There was no or limited evidence that milk consumption
affects the risk of bladder, breast, and prostate cancer.
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